+

WO2002032408A3 - Combinations of a thyromimetic compound and a statin - Google Patents

Combinations of a thyromimetic compound and a statin Download PDF

Info

Publication number
WO2002032408A3
WO2002032408A3 PCT/EP2001/012075 EP0112075W WO0232408A3 WO 2002032408 A3 WO2002032408 A3 WO 2002032408A3 EP 0112075 W EP0112075 W EP 0112075W WO 0232408 A3 WO0232408 A3 WO 0232408A3
Authority
WO
WIPO (PCT)
Prior art keywords
statin
combinations
thyromimetic compound
thyromimetic
methods
Prior art date
Application number
PCT/EP2001/012075
Other languages
French (fr)
Other versions
WO2002032408A2 (en
Inventor
Ronald Edward Steele
Beatriz N Dardik
Original Assignee
Novartis Ag
Novartis Pharma Gmbh
Ronald Edward Steele
Beatriz N Dardik
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Novartis Pharma Gmbh, Ronald Edward Steele, Beatriz N Dardik filed Critical Novartis Ag
Priority to AU2002223626A priority Critical patent/AU2002223626A1/en
Publication of WO2002032408A2 publication Critical patent/WO2002032408A2/en
Publication of WO2002032408A3 publication Critical patent/WO2002032408A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Disclosed are methods for the treatment of conditions associated with elevated levels of Lp(a), such as CHD, ischaemic stroke, restenosis after angioplasty, peripheral vascular disease, intermittent claudication, reduction in necrosis after myocardial infarction, dyslipidemia and post-prandial lipemia. The methods include administration of a therapeutically effective amount of a pharmaceutical combination of a thyromimetic compound and a statin.
PCT/EP2001/012075 2000-10-20 2001-10-18 Combinations of a thyromimetic compound and a statin WO2002032408A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002223626A AU2002223626A1 (en) 2000-10-20 2001-10-18 Combinations of a thyromimetic compound and a statin

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24203600P 2000-10-20 2000-10-20
US60/242,036 2000-10-20

Publications (2)

Publication Number Publication Date
WO2002032408A2 WO2002032408A2 (en) 2002-04-25
WO2002032408A3 true WO2002032408A3 (en) 2003-10-02

Family

ID=22913212

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/012075 WO2002032408A2 (en) 2000-10-20 2001-10-18 Combinations of a thyromimetic compound and a statin

Country Status (2)

Country Link
AU (1) AU2002223626A1 (en)
WO (1) WO2002032408A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8933083B2 (en) 2003-01-14 2015-01-13 Arena Pharmaceuticals, Inc. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1262177B1 (en) * 2001-05-31 2006-08-23 Pfizer Products Inc. Medical use of thyromimetic compounds to treat hair loss and compositions
AU2004257267B2 (en) 2003-07-14 2009-12-03 Arena Pharmaceuticals,Inc Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
US7829552B2 (en) 2003-11-19 2010-11-09 Metabasis Therapeutics, Inc. Phosphorus-containing thyromimetics
CA2573223C (en) 2004-08-06 2013-05-21 Otsuka Pharmaceutical Co., Ltd. Aromatic compound
JP2008542301A (en) 2005-05-26 2008-11-27 メタバシス・セラピューティクス・インコーポレイテッド Thyroid hormone-like drug for the treatment of fatty liver disease
RU2444362C2 (en) 2005-12-05 2012-03-10 Оцука Фармасьютикал Ко., Лтд. Drug preparation
CN100371709C (en) * 2005-12-12 2008-02-27 重庆医药工业研究院有限责任公司 Method for separating and determining pitavastatin and its optical isomer by means of liquid chromatography
UA95978C2 (en) 2006-10-02 2011-09-26 Оцука Фармас'Ютікел Ко., Лтд. Stat3/5 activation inhibitor
WO2012040279A1 (en) 2010-09-22 2012-03-29 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
KR102595163B1 (en) 2015-01-06 2023-10-30 아레나 파마슈티칼스, 인크. Methods for Treating Conditions Associated with the S1P1 Receptor
WO2016209809A1 (en) 2015-06-22 2016-12-29 Arena Pharmaceuticals, Inc. Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid(compound1) for use in sipi receptor-associated disorders
US11202789B2 (en) 2016-11-21 2021-12-21 Viking Therapeutics, Inc. Method of treating glycogen storage disease
JP2020507611A (en) 2017-02-16 2020-03-12 アリーナ ファーマシューティカルズ， インコーポレイテッド Compounds and methods for the treatment of primary biliary cholangitis
CA3064940A1 (en) 2017-06-05 2018-12-13 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis
JP2021518403A (en) 2018-03-22 2021-08-02 バイキング・セラピューティクス・インコーポレイテッド Crystal form of compound and method of producing crystal form of compound
CN112601516A (en) 2018-06-06 2021-04-02 艾尼纳制药公司 Treatment with S1P1Methods of receptor-related conditions
EP3890747A4 (en) 2018-12-05 2022-08-03 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis and inflammation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000051971A1 (en) * 1999-03-01 2000-09-08 Pfizer Products Inc. Oxamic acids and derivatives as thyroid receptor ligands
WO2000058279A1 (en) * 1999-03-29 2000-10-05 Novartis Ag Diaryl derivatives and their use as medicaments

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000051971A1 (en) * 1999-03-01 2000-09-08 Pfizer Products Inc. Oxamic acids and derivatives as thyroid receptor ligands
WO2000058279A1 (en) * 1999-03-29 2000-10-05 Novartis Ag Diaryl derivatives and their use as medicaments

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HARWOOD H J ET AL: "MODULATORS OF DYSLIPIDAEMIA", EMERGING DRUGS, ASHLEY PUBLICATIONS, LONDON, GB, 1998, pages 147 - 172, XP008002918, ISSN: 1361-9195 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8933083B2 (en) 2003-01-14 2015-01-13 Arena Pharmaceuticals, Inc. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia

Also Published As

Publication number Publication date
WO2002032408A2 (en) 2002-04-25
AU2002223626A1 (en) 2002-04-29

Similar Documents

Publication Publication Date Title
WO2002032408A3 (en) Combinations of a thyromimetic compound and a statin
WO2004006858A3 (en) Compounds, compositions, and methods employing same
WO2004005281A8 (en) Inhibitors of tyrosine kinases
WO2000055126A3 (en) N-cyanomethylamides as protease inhibitors
EE200200201A (en) A tyrosine kinase inhibiting compound, a pharmaceutical composition comprising it, and a therapeutic use.
WO2005056547A3 (en) Quinoxalines useful as inhibitors of protein kinases
WO2002098444A3 (en) Use of hepcidin for preparing a medicament for treating disorders of iron homeostasis
WO2006004833A3 (en) Pyrrolotriazine kinase inhibitors
EP2527342A3 (en) Derivatives of UK-2A
EP1769791A3 (en) Treatment of Alzheimer's disease with cell cycle inhibitors
WO2000056296A3 (en) Compositions for improving fertility
WO2003053359A3 (en) 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
WO2006041773A3 (en) Lactam compounds useful as protein kinase inhibitors
HK1080459A1 (en) Novel pyrimidineamide derivatives and the use thereof
WO2000045800A3 (en) Immunosurpressive effects of pteridine derivatives
WO2004004774A3 (en) Compositions comprising panthetine for the treatment of dyslipidemia
MXPA03010761A (en) Pharmaceutical combinations.
HK1092693A1 (en) Pharmaceutical compositions comprising ascorbic acid for the treatment of fungal superfinfections and fungal recurrences
WO2003039453A3 (en) Novel benzoyl peroxide compositions for the treatment of dermatological disorders and methods for their use
WO2005105094A3 (en) Cancer treatment method
WO2003099202A3 (en) Beta-secretase inhibitors
WO2002080911A3 (en) Use of substituted imidazo[1,2-a]-pyridine-3-yl-amide and imidazo[1,2-a]-pyridine-3-yl-amine compounds as medicaments for the treatment of neurodegenerative diseases
WO2005123068A3 (en) Methods of dealying alzheimer’s disease progression using a beta-amyloid precursor protein inhibitor and a hmg coa reductase inhibitor
WO2003080800A3 (en) Prevention and treatment of disease using angiogenesis-and/or tumor antigens
WO2002022112A3 (en) Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载